Nancy Baum Lipsitz remembers the night the pain began. She’d had a glass of white wine with a friend and went to bed with a terrible headache. The next day, she still felt horrible, the beginning of what she called a “rolling tide” of near constant migraines and lower level headaches.
Read The Article in Health & Science, WhasingtonPost.com >>>
Ajovy is first anti-CGRP treatment available at monthly and quarterly doses
|The third new generation of CGRP antibody has been approved. It’s called Emgality (galcanezumab) which was just approved by the FDA on September 27th.
Read the article in MigraineAgain.com >>>
Eli Lilly announces that the European Commission (EC) has approved the commercialization of galcanezumab (Emgality) as a prophylactic treatment of migraine in adults suffering from at least four days of migraine per month.
Galcanezumab is a humanized monoclonal antibody that binds to the peptide related to the calcite gene (CGRP, for its acronym in English) associated with episodes of migraine, blocks its function
Läs artikeln på EMHAnews.com >>>